Literature DB >> 31925819

Treating sickle cell anemia: A new era dawns.

Martin H Steinberg1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31925819     DOI: 10.1002/ajh.25724

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

Review 1.  Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.

Authors:  Debra L Stevens; Meri Hix; Brooke L Gildon
Journal:  J Pharm Technol       Date:  2021-04-19

Review 2.  L-glutamine for sickle cell disease: more than reducing redox.

Authors:  Firas Jafri; Gyuhee Seong; Tim Jang; Emanuela Cimpeanu; Maria Poplawska; Dibyendu Dutta; Seah H Lim
Journal:  Ann Hematol       Date:  2022-05-14       Impact factor: 4.030

Review 3.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

4.  Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.

Authors:  Zachary Baldwin; Boshen Jiao; Anirban Basu; Joshua Roth; M A Bender; Zizi Elsisi; Kate M Johnson; Emma Cousin; Scott D Ramsey; Beth Devine
Journal:  Pharmacoecon Open       Date:  2022-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.